Innovative cancer research reveals mechanisms and therapies reshaping oncology. Bispecific innate cell engager AFM28 targets CD123+ leukemic stem cells in AML and MDS, offering new immunotherapy avenues. Another study identifies the GATOR1 complex as a tumor suppressor in Myc-driven lymphoma via CRISPR screens. Additionally, the interplay of adipocyte IL6 and cancer CXCL1 drives STAT3/NF-κB crosstalk, fostering triple-negative breast cancer progression, offering targets for therapeutic intervention.